Breast Cancer Phenotype Associated With Li-Fraumeni Syndrome: A Brazilian Cohort Enriched by

Li-Fraumeni syndrome R337H TP53 early-onset breast cancer hereditary breast cancer

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 16 12 2021
accepted: 14 02 2022
entrez: 4 4 2022
pubmed: 5 4 2022
medline: 5 4 2022
Statut: epublish

Résumé

Breast cancer (BC) is the most prevalent malignancy in women with Li-Fraumeni syndrome (LFS). The literature on BC in LFS is limited due to its rarity worldwide. A The aim of the study was to describe the BC phenotype expressed by Brazilian female LFS carriers and compare the data between p.R337H and other We searched for cases of Among 163 adult female carriers from the registry, 91 (56%) had received a BC diagnosis, including 72 p.R337H carriers. BC was the first cancer diagnosed in 90% of cases. Early onset BC (age ≤45 years) was diagnosed in 78.2% of cases (11.5% <31 years; 66.7% 31-45 years; 21.8% >45 years). The median age of BC diagnosis for p.R337H carriers was 39.5 years (range 20-69 years) compared to 34 years (range 21-63 years) for non-p.R337H carriers (p = 0.009). In total, 104 breast tumors were observed in 87 women. Bilateral BC was observed in 29.3% of cases. Histology was available for 96 tumors, comprising 69 invasive breast carcinomas, which were mostly invasive ductal carcinomas (95.6%), 25 ductal The expressed phenotype of p.R337H is similar to that of other

Identifiants

pubmed: 35371985
doi: 10.3389/fonc.2022.836937
pmc: PMC8966034
doi:

Types de publication

Journal Article

Langues

eng

Pagination

836937

Informations de copyright

Copyright © 2022 Sandoval, Polidorio, Leite, Cartaxo, Pisani, Quirino, Cezana, Pereira, Pereira, Rossi and Achatz.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Cancer. 2016 Dec 1;122(23):3673-3681
pubmed: 27496084
J Med Genet. 2010 Jun;47(6):421-8
pubmed: 20522432
Fam Cancer. 2020 Jan;19(1):47-53
pubmed: 31748977
Cancers (Basel). 2020 Feb 07;12(2):
pubmed: 32045981
J Natl Cancer Inst. 2014 Nov 30;107(1):380
pubmed: 25435542
Breast Cancer Res Treat. 2012 Jun;133(3):1125-30
pubmed: 22392042
CA Cancer J Clin. 2020 Sep;70(5):355-374
pubmed: 32813307
PLoS One. 2014 Jun 17;9(6):e99893
pubmed: 24936644
ESMO Open. 2021 Dec;6(6):100289
pubmed: 34678571
Cancer Res. 2020 Jan 15;80(2):347-353
pubmed: 31719099
Nat Rev Dis Primers. 2019 Sep 23;5(1):66
pubmed: 31548545
Mod Pathol. 2021 Mar;34(3):542-548
pubmed: 32636452
Ann Oncol. 2015 Aug;26(8):1533-46
pubmed: 25939896
Curr Opin Oncol. 2018 Jan;30(1):23-29
pubmed: 29076966
Cancer Res. 1988 Sep 15;48(18):5358-62
pubmed: 3409256
Rep Pract Oncol Radiother. 2021 Apr 14;26(2):179-187
pubmed: 34211767
Eur J Hum Genet. 2020 Oct;28(10):1379-1386
pubmed: 32457520
Cancer Res. 1991 Nov 15;51(22):6094-7
pubmed: 1933872
Hum Mutat. 2021 Mar;42(3):223-236
pubmed: 33300245
Breast Care (Basel). 2020 Jun;15(3):253-259
pubmed: 32774219
J Clin Oncol. 2020 Apr 20;38(12):1346-1366
pubmed: 31928404
Cancer. 2020 Nov 1;126(21):4678-4686
pubmed: 32875577
Genes Cancer. 2011 Apr;2(4):475-84
pubmed: 21779515
Hum Mutat. 2010 Feb;31(2):143-50
pubmed: 19877175
Hered Cancer Clin Pract. 2017 Jul 26;15:11
pubmed: 28770017
Pediatr Blood Cancer. 2019 May;66(5):e27629
pubmed: 30719841
Hum Genome Var. 2014 Oct 16;1:14012
pubmed: 27081505
Cancer Res. 2003 Oct 15;63(20):6643-50
pubmed: 14583457
Hum Mutat. 2020 Sep;41(9):1555-1562
pubmed: 32485079
JAMA Oncol. 2021 Dec 1;7(12):1800-1805
pubmed: 34709361
Lancet Oncol. 2016 Sep;17(9):1295-305
pubmed: 27501770
BMC Cancer. 2008 Dec 01;8:357
pubmed: 19046423
J Clin Oncol. 2009 Mar 10;27(8):1250-6
pubmed: 19204208
J Clin Oncol. 2015 Jul 20;33(21):2345-52
pubmed: 26014290
Fam Cancer. 2015 Jun;14(2):333-6
pubmed: 25564201
PLoS One. 2021 Feb 19;16(2):e0247363
pubmed: 33606809
PLoS One. 2021 Sep 16;16(9):e0251639
pubmed: 34529667
J Clin Oncol. 2009 Sep 10;27(26):e108-9; author reply e110
pubmed: 19652052
J Med Genet. 2010 Nov;47(11):771-4
pubmed: 20805372
J Pathol Clin Res. 2019 Jul;5(3):189-198
pubmed: 31041842
Cancer Lett. 2007 Jan 8;245(1-2):96-102
pubmed: 16494995
Cancer. 2012 Feb 15;118(4):908-13
pubmed: 21761402
Breast Cancer Res Treat. 2022 Jan;191(1):159-167
pubmed: 34652547
PLoS One. 2018 Dec 31;13(12):e0209934
pubmed: 30596752
Sci Rep. 2020 Oct 6;10(1):16614
pubmed: 33024147
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9330-5
pubmed: 11481490

Auteurs

Renata Lazari Sandoval (RL)

Oncology Center, Hospital Sírio-Libanês, Brasília, Brazil.

Natalia Polidorio (N)

Oncology Center, Hospital Sírio-Libanês, Brasília, Brazil.

Ana Carolina Rathsam Leite (ACR)

Oncology Center, Hospital Sírio-Libanês, Brasília, Brazil.

Mariana Cartaxo (M)

Oncology Center, Hospital Nossa Senhora das Neves, João Pessoa, Brazil.

Janina Pontes Pisani (JP)

Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil.

Carla Vanessa Quirino (CV)

Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil.

Loureno Cezana (L)

Oncology Center, Hospital Santa Rita de Cássia, Vitoria, Brazil.

Natálya Gonçalves Pereira (NG)

Genetics and Genomics Department, Beneficência Portuguesa, São Paulo, Brazil.

Allan Andresson Lima Pereira (AAL)

Oncology Center, Hospital Sírio-Libanês, Brasília, Brazil.

Benedito Mauro Rossi (BM)

Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil.
Genetics and Genomics Department, Beneficência Portuguesa, São Paulo, Brazil.

Maria Isabel Achatz (MI)

Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil.

Classifications MeSH